Back to results
US 2019/0167655 A1Published application
Transdermal Administration Of Fentanyl And Analogs Thereof
OwnerSubramanian VENKATRAMAN, Shaoling Li +3inventors
InventorsSubramanian VENKATRAMAN, Shaoling Li, Robert M. Gale, Jane Stepic, William W. Van Osdol
Life of this patent
Estimating the term…
Abstract
A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.
Claims34
A transdermal patch for administering fentanyl or an analog thereof through the skin comprising:
- (a) a backing layer;
- and
- (b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive;
- said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition free of undissolved fentanyl or an analog thereof and containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days.
1 more element
A monolithic transdermal patch for administering fentanyl through the skin comprising:
- (a) a backing layer;
- and
- (b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive;
- said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition to be free of undissolved components and containing an amount of fentanyl sufficient to induce and maintain analgesia in a human for at least three days.
1 more element
A transdermal patch for administering sufentanil through the skin comprising:
- (a) a backing layer;
- and
- (b) polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive;
- said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition to be free of undissolved sufentanil and containing an amount of sufentanil sufficient to induce and maintain analgesia in a human for at least three days.
1 more element
Dependencies are inferred from the claim text.